TEL AVIV, Israel, March 03, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today that Chief Executive Officer, Dror Harats, M.D., will provide a corporate and business overview at the 28th annual ROTH conference in Dana Point, CA and at the Alliance for Regenerative Medicine (ARM) Cell & Gene Therapy Investor Day in New York.
|ROTH Presentation Details:|
|Title:||The 28th Annual ROTH Conference|
|Date:||March 14th, 2016|
|Time:||11:00-11:30 AM, Pacific Time|
|Location:||The Ritz Carlton hotel, Dana Point, CA|
|Room name:||(D) Salon 6 - yellow|
|Cell & Gene Therapy Presentation Details:|
|Title:||ARM Cell & Gene Therapy Investor Day|
|Date:||March 22nd, 2016|
|Time:||5:05 – 5:20 PM, Eastern Time|
|Location:||Metropolitan Club, New York|
|Room name:||West Lounge Room|
About the ARM Cell & Gene Therapy Investor Day
ARM’s Cell & Gene Therapy Investor Day is a full-day conference combining discussions between key opinion leaders, top analysts and senior executives in addition to presentations by the field’s most promising companies. The event includes clinical and commercial experts who are on-hand to address specific questions, as well as offer insight into how cell and gene therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. This meeting is open for credentialed investors and members of the media. RSVP is required. For more information, please go to http://arminvestorday.com.
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company's lead oncology product candidate, VB-111, is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. VB-111 is conveniently administered as an IV infusion once every two months. It has demonstrated safety in >170 cancer patients and efficacy signals in an `all comers` Ph1 trial as well as in three tumor-specific Ph2 studies. The mechanism of VB-111 combines blockade of tumor vasculature with an anti-tumor immune response. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor. VB-111 is currently being studied in a Ph3 pivotal trial for Recurrent Glioblastoma (rGBM); the trial is being conducted under an FDA Special Protocol Assessment (SPA), fast track and Orphan designation.
INVESTOR CONTACT: Michael Rice, Founding Partner LifeSci Advisors, LLC 646-597-6979
Source: VBL Therapeutics